NASDAQ:BOLD - Audentes Therapeutics Stock Price, News, & Analysis

Sign in or create an account to add this stock to your watchlist.
$27.22 +0.22 (+0.81 %)
(As of 10/23/2018 04:00 PM ET)
Previous Close$27.00
Today's Range$26.09 - $27.75
52-Week Range$24.51 - $46.18
Volume14,171 shs
Average Volume700,298 shs
Market Capitalization$1.01 billion
P/E Ratio-8.03
Dividend YieldN/A
Beta0.73
Audentes Therapeutics, Inc., a clinical stage biotechnology company, focuses on developing and commercializing gene therapy products for patients suffering from diseases caused by single gene defects. The company is developing AT132, which is in Phase I/II clinical studies for the treatment of X-linked myotubular myopathy (XLMTM); AT342 that is in Phase I/II clinical studies to treat crigler-najjar syndrome; AT982, which is in preclinical studies for the treatment of pompe disease; and AT307 that is in preclinical studies to treat CASQ2 subtype of catecholaminergic polymorphic ventricular tachycardia. Audentes Therapeutics, Inc. has a collaborative development agreement with Genethon to research, develop, manufacture, and commercialize products for the treatment of XLMTM; and license and collaboration agreement with the University of Pennsylvania to research, develop, sell, and import licensed products for the treatment of crigler-najjar. The company was founded in 2012 and is headquartered in San Francisco, California.

Receive BOLD News and Ratings via Email

Sign-up to receive the latest news and ratings for BOLD and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Stock Exchange NASDAQ
Industry Biological products, except diagnostic
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:BOLD
Previous Symbol
CUSIPN/A
Phone415-818-1001

Debt

Debt-to-Equity RatioN/A
Current Ratio19.06
Quick Ratio19.06

Price-To-Earnings

Trailing P/E Ratio-8.03
Forward P/E Ratio-8.22
P/E GrowthN/A

Sales & Book Value

Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book Value($5.38) per share
Price / Book-5.06

Profitability

EPS (Most Recent Fiscal Year)($3.40)
Net Income$-90,230,000.00
Net MarginsN/A
Return on EquityN/A
Return on Assets-38.04%

Miscellaneous

Employees152
Outstanding Shares37,330,000
Market Cap$1.01 billion
OptionableN/A

Audentes Therapeutics (NASDAQ:BOLD) Frequently Asked Questions

What is Audentes Therapeutics' stock symbol?

Audentes Therapeutics trades on the NASDAQ under the ticker symbol "BOLD."

How were Audentes Therapeutics' earnings last quarter?

Audentes Therapeutics Inc (NASDAQ:BOLD) posted its quarterly earnings data on Wednesday, August, 8th. The biotechnology company reported ($0.85) earnings per share for the quarter, missing the Zacks' consensus estimate of ($0.78) by $0.07. View Audentes Therapeutics' Earnings History.

When is Audentes Therapeutics' next earnings date?

Audentes Therapeutics is scheduled to release their next quarterly earnings announcement on Tuesday, November 13th 2018. View Earnings Estimates for Audentes Therapeutics.

What price target have analysts set for BOLD?

12 brokers have issued 1-year target prices for Audentes Therapeutics' shares. Their predictions range from $20.00 to $49.00. On average, they expect Audentes Therapeutics' stock price to reach $35.00 in the next twelve months. This suggests a possible upside of 27.6% from the stock's current price. View Analyst Price Targets for Audentes Therapeutics.

What is the consensus analysts' recommendation for Audentes Therapeutics?

12 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Audentes Therapeutics in the last year. There are currently 2 sell ratings, 4 hold ratings and 6 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Audentes Therapeutics.

What are Wall Street analysts saying about Audentes Therapeutics stock?

Here are some recent quotes from research analysts about Audentes Therapeutics stock:
  • 1. HC Wainwright analysts commented, "Our Buy rating and $40 price target on shares of Audentes are based on sum-of-the-parts analysis of the company’s pipeline. We value the XLMTM commercial opportunity at $21/share, and CN at $19/share, each of which are based on a 5x P/ S multiple on peak sales of roughly $579M (XLMTM peak sales of about $300M and CN peak sales of approximately $279M in FY2025), discounted at 10% over an 8-year period. Our 5x P/S multiple is below the lower end of historic M&A within the sector (typically in the range of 7-9x)." (10/8/2018)
  • 2. Mizuho analysts commented, "We expect to see new data out to 48 weeks from the earlier patients treated in Cohort 1 as well as initial efficacy and safety data from the first patient treated in the higher dose Cohort 2. We are optimistic ahead of the data and we expect to see stabilization for patient # 1-3 in Cohort 1, Continued improvement on patient 5 and signs of efficacy on the latest patients enrolled (Patient 6 and 7). This could be a share moving event." (10/3/2018)
  • 3. According to Zacks Investment Research, "Audentes Therapeutics, Inc. is a biotechnology company which focused on developing and commercializing gene therapy products for patients suffering from serious, life-threatening rare diseases. The company's product pipeline consists of AT132 for the treatment of X-linked myotubular myopathy; AT342 for the treatment of crigler-najjar syndrome type 1; AT307 for the treatment of the CASQ2 subtype of catecholaminergic polymorphic ventricular tachycardia and AT982 for the treatment of pompe disease, which are in pre-clinical trial stage. Audentes Therapeutics, Inc. is based in San Francisco, California. " (8/9/2018)
  • 4. Chardan Capital analysts commented, "We initiate coverage on Neutral rating (PT$35): While we see the company’s initial phase I/II results with AAV-based gene therapies (GT) as promising, we see more constrained market opportunities due to small patient populations. Audentes has developed 4 assets to target rare/ultra-rare diseases of the liver, heart, or skeletal muscle. The lead product candidate, AT132, is an AAV8-based GT being tested in the phase I/II ASPIRO trial (NCT03199469) as a treatment for X-linked myotubular myopathy (XLMTM). The 2nd clinical stage asset is AT342, an AAV8-based GT in the phase I/II VALENS trial (NCT03223194) for Crigler-Najjar syndrome (CN). 2 additional products, AT982 for Pompe disease and AT307 for CASQ2-CPVT, are in preclinical development." (6/25/2018)
  • 5. Raymond James analysts commented, "We are maintaining our Market Perform rating on BOLD. Therapy (ASGCT) annual meeting, the company provided an update on the ongoing Phase I/II ASPIRO study of AT132 for X-linked myotubular myopathy (XLMTM). By comparing the results of the ASPIRO study and those of the INCEPTUS trial, in our opinion, the totality of the updated data continues to suggest that AT132 provides a significant benefit to patients suffering with XLMTM, which may lead to an accelerated regulatory pathway. That said, we remain cautiously optimistic about the commercial prospect of this product given rare nature of the disease being pursued." (5/17/2018)

Who are some of Audentes Therapeutics' key competitors?

Who are Audentes Therapeutics' key executives?

Audentes Therapeutics' management team includes the folowing people:
  • Mr. Matthew R. Patterson, Co-Founder, CEO & Director (Age 46)
  • Ms. Natalie C. Holles, Pres & COO (Age 45)
  • Mr. Thomas P. Soloway, Sr. VP & CFO (Age 51)
  • Dr. John T. Gray, Sr. VP & Chief Scientific Officer (Age 55)
  • Mr. Andrew H. Chang, Director of Investor Relations

When did Audentes Therapeutics IPO?

(BOLD) raised $75 million in an IPO on Wednesday, July 20th 2016. The company issued 5,000,000 shares at a price of $14.00-$16.00 per share. BofA Merrill Lynch, Cowen and Company and Piper Jaffray served as the underwriters for the IPO and Wedbush PacGrow was co-manager.

How do I buy shares of Audentes Therapeutics?

Shares of BOLD can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Audentes Therapeutics' stock price today?

One share of BOLD stock can currently be purchased for approximately $27.43.

How big of a company is Audentes Therapeutics?

Audentes Therapeutics has a market capitalization of $1.01 billion. The biotechnology company earns $-90,230,000.00 in net income (profit) each year or ($3.40) on an earnings per share basis. Audentes Therapeutics employs 152 workers across the globe.

What is Audentes Therapeutics' official website?

The official website for Audentes Therapeutics is http://www.audentestx.com.

How can I contact Audentes Therapeutics?

Audentes Therapeutics' mailing address is 600 CALIFORNIA ST. 17TH FLOOR, SAN FRANCISCO CA, 94108. The biotechnology company can be reached via phone at 415-818-1001 or via email at [email protected]


MarketBeat Community Rating for Audentes Therapeutics (NASDAQ BOLD)

Community Ranking:  2.7 out of 5 (star star)
Outperform Votes:  218 (Vote Outperform)
Underperform Votes:  193 (Vote Underperform)
Total Votes:  411
MarketBeat's community ratings are surveys of what our community members think about Audentes Therapeutics and other stocks. Vote "Outperform" if you believe BOLD will outperform the S&P 500 over the long term. Vote "Underperform" if you believe BOLD will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 10/23/2018 by MarketBeat.com Staff

Featured Article: Conference Calls

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel